Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

Crescita Therapeutics Inc. Announces Closing of Arrangement

Crescita Therapeutics Closes $0.80 All-Cash Acquisition by ClinActiv, Delisting TSX and Cashing Out Shareholders

By The Northwire Desk — AI Analysis Jun 03, 2026 · 18:07 CTX · 0.79 CRESCITA THERAPEUTICS INC. J
Executive Summary
  • On June 3, 2026, Crescita Therapeutics Inc. officially closed its previously announced plan of arrangement with ClinActiv Holdings Inc.
  • All outstanding common shares were acquired for $0.80 per share in an all-cash transaction.
  • Following the closing, Crescita's shares are delisted from the Toronto Stock Exchange (TSX), and the company will apply to cease being a reporting issuer under Canadian securities laws.
  • This event marks the final execution step of a transaction first announced on March 14, 2026.
Material Impact
  • The transaction was announced on March 14, 2026, at a 74% premium to the five-day VWAP. The stock immediately repriced from ~$0.47 to ~$0.73.
  • Historical progression shows flawless execution of all regulatory and shareholder milestones: shareholder approval was obtained on May 14, 2026 (99.58% in favor), followed by final court approval on May 20, 2026.
  • The stock traded in a tight consolidation band between $0.74 and $0.76 from mid-March through early June, reflecting efficient market pricing of the $0.80 cash exit.
  • The June 3 closing confirms the deal terms without deviation. There is no new fundamental catalyst, no change in valuation, and no upside premium remaining. The market has already fully priced in the cash-out.
  • From a risk-averse perspective, the event is a routine execution of a known outcome. Shareholders holding through the close receive the promised liquidity, but the stock ceases to trade, eliminating any future price discovery or dividend potential.
CTX · Price
Company Overview
  • Crescita Therapeutics operates in the dermatology and aesthetic skincare space, combining commercial product sales with contract manufacturing services.
  • Flagship initiatives include the integration of Laboratoire Provence-Canada Inc. assets (acquired for $775k, fair value ~$1.38M), which added the Bacti Control® brand and manufacturing equipment.
  • The company secured an exclusive five-year supply agreement with a former LPC CMO client, boosting recurring manufacturing revenue.
  • Operational highlights include a five-year lease renewal for its manufacturing and office facility through September 2031, securing long-term operational stability.
  • Q1 2026 results showed revenue growth of 59% YoY to $5.6M, driven by manufacturing volumes and skincare sales, though net losses widened due to $0.8M in transaction costs.
Read the original news release →

More from CRESCITA THERAPEUTICS INC. J

Jun 01, 2026 · 20:59

Crescita Therapeutics Inc.

M&A / Property May 20, 2026 · 17:07

Crescita Therapeutics Secures Final Court Approval for ClinActiv Acquisition; Shares Trade Near Offer Price

M&A / Property May 14, 2026 · 13:48

Crescita shareholders overwhelmingly back ClinActiv buyout, paving the way for a clean exit at the premium offer.

M&A / Property May 11, 2026 · 07:30

Crescita Shares Trade Near Buyout Price as Q1 EBITDA Turnaround Validates Deal Viability

Earnings Apr 22, 2026 · 19:13

Crescita Therapeutics Moves Closer to ClinActiv Takeover at $0.80 Premium

M&A / Property Mar 31, 2026 · 07:30

Crescita Locks $0.80 Buyout as Q4 Earnings Validate Manufacturing Pivot

Earnings